International Stem Cell Corporation Granted Key Patent in US

International Stem Cell Corporation (OTCQB:ISCO) a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a key patent (US9926529B2) on the method used to manufacture ISC-hpNSC. These are the cells administered in ISCO’s ongoing Parkinson’s disease clinical trial, and they can potentially be utilized in therapies to treat traumatic brain injury and stroke.

As quoted in the press release:

The new technique developed by ISCO’s scientists outperforms the traditional methods because it produces a more pure population of NSCs, generating NSCs that are over 95% pure, as opposed to traditional methods that only yield purities of around 80%. In addition, ISCO’s method is automatable and less labor intensive.

“Year after year, ISCO continues to strengthen its position as a leader in the field of regenerative medicine and explore the full potential of hpSCs,” said Russell Kern, PhD, ISCO’s Executive Vice President and Chief Scientific Officer. “This new patent adds to the strong intellectual property of the company and positions us to extend our scientific reach to new heights,” he continues.

Click here to read the full press release.